Physician profile
Lynsey Rather
NPI 1518634245
$3,445.24
in general payments reported to CMS, 2019-2025
15 companies · $661 in 2025
The $661 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.38 · 2022: $713 · 2023: $1,172 · 2024: $888 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,720.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,178.92 | 2022-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $892.44 | 2022-2025 | |
| Ucb, INC. | $608.98 | 2022-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $289.19 | 2021-2025 | Benlysta |
| Radius Health, INC. | $240.79 | 2022-2025 | Tymlos |
| Astrazeneca Pharmaceuticals Lp | $44.95 | 2022-2023 | Saphnelo |
| Actelion Pharmaceuticals US, INC. | $27.23 | 2025 | Opsynvi |
| Bioventus LLC | $25.10 | 2023 | Durolane |
| Novartis Pharmaceuticals Corporation | $24.91 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.42 | 2025 | Ofev |
| Ani Pharmaceuticals, INC. | $23.37 | 2024 | Purified Cortrophin Gel |
| Organon LLC | $21.97 | 2022-2025 | Hadlima |
| Depuy Synthes Sales INC. | $16.01 | 2024 | Monovisc |
| Horizon Therapeutics Plc | $14.34 | 2023 | Krystexxa |
| Janssen Biotech, INC. | $13.62 | 2023 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynsey Rather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.